Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient

Highlights • Afatinib is a tyrosine kinase inhibitor for first-line therapy in advanced non-small cell lung cancer. • Stevens-Johnson syndrome related to EGFR directed tyrosin kinase inhibitors as a rare adverse event. • first case report of SJS during afatinib treatment

Saved in:
Bibliographic Details
Published inLung cancer (Amsterdam, Netherlands) Vol. 95; pp. 35 - 38
Main Authors Doesch, Janine, Debus, Dirk, Meyer, Christian, Papadopoulos, Thomas, Schultz, Erwin S, Ficker, Joachim H, Brueckl, Wolfgang M
Format Journal Article
LanguageEnglish
Published Ireland Elsevier Ireland Ltd 01.05.2016
Subjects
Adrenal Cortex Hormones - therapeutic use
Afatinib
Aged
Female
Hematology, Oncology and Palliative Medicine
Humans
Lung Neoplasms - complications
Lung Neoplasms - diagnosis
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Mutation
NSCLC
Protein Kinase Inhibitors - adverse effects
Pulmonary/Respiratory
Quinazolines - adverse effects
Receptor, Epidermal Growth Factor - genetics
SJS
Skin - pathology
Stevens-Johnson Syndrome - diagnosis
Stevens-Johnson Syndrome - drug therapy
Stevens-Johnson Syndrome - etiology
TKI
Treatment Outcome
TKI
NSCLC
Afatinib
SJS
Online AccessGet full text

Cover

More Information
Summary:Highlights • Afatinib is a tyrosine kinase inhibitor for first-line therapy in advanced non-small cell lung cancer. • Stevens-Johnson syndrome related to EGFR directed tyrosin kinase inhibitors as a rare adverse event. • first case report of SJS during afatinib treatment
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2016.02.015